Home > Priyanka Sharma, ASCO20: New Combination Therapy in the Treatment of Triple-Negative Breast Cancer
Breast Cancer

Priyanka Sharma, ASCO20: New Combination Therapy in the Treatment of Triple-Negative Breast Cancer

Published Online: June 8th 2020

Priyanka Sharma, University of Kansas, joins us to discuss the data from the SWOG S1416 study (Clinicaltrials.gov identifier: NCT02595905) presented at the ASCO20 Virtual Scientific Programe on the combined use of PARP inhibitors and chemotherapy in the treatment of triple-negative breast cancer.

Questions

1. What are the major unmet needs in the treatment of triple-negative breast cancer? (0:06)

2. What is the rationale for the combined use of cisplatin and veliparib in metastatic triple-negative breast cancer? (0:49)

3. Early studies of combined PARP inhibitors/chemotherapy have been challenging due to exacerbation of myelosuppression. How does veliparib overcome this? (2:20)

4. Could you tell us a little about the SWOG S1416 study and its efficacy and safety findings? (3:20)

5. What are the next steps for this combined therapy? (5:10)

 

Speaker disclosure: Priyanka Sharma has no financial or non-financial relationships or activities to declare in relation to this video.

Support: Interview and filming supported by Touch Medical Media.

Filmed in coverage of the 2020 ASCO Virtual Scientific Program.

Related Videos In Breast Cancer
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down crosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots padlock person play_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar